摘要
目的观察吉西他滨单药治疗老年晚期非小细胞肺癌疗效,临床受益反应(CBR)及毒性反应。方法29例ⅢB～Ⅵ期老年非小细胞肺癌患者单用吉西他滨1000mg/m2,第1,8天静滴,每21天为1周期,按WHO标准评估疗效及毒副反应,同时评估CBR指标。结果CR为0,PR8例,NC14例,PD7例,有效率为27.6%,CBR为80%。毒副反应轻,老年患者也能耐受。结论吉西他滨单药治疗疗效好,低毒安全。
Objective To evaluate the clinical efficiency, clinical-benefit respose （CBR） and toxicity of Gemcitabine single-agent in the traeatment of elderly advanced non-small -cell lung cancer patients. Methods 29 elderly patients with grent III B/IV were treated with Geacitabine 1000mg/m^2 on the first and eighth day in each 21-day cycle. The clinical efficacy and toxicity were estimated accoriding to the standard of WHO and the CBR was evaluated simultaneously.Results There were 8 partial resposes, 14 no changes and 7 progressive diseases. The effcieny rate is 27.6%. The CBR rate was reached 80%, in 29 patients.The toxicity was mild and well tolerated for elderly patients.Conclusions Gemcitabine single-agent in the treatment of elderly advanced non-small-cell lung cancer is highly effective, low toxic and safe.
出处
《当代医学》
2009年第9期1-2,共2页
Contemporary Medicine
关键词
癌
非小细胞肺/药物疗法
吉西他滨
老年患者
单药化学
Carcinoma
non-small cell lung/drug therapy
Gemcitabine
The elderly
Single-agent chemotherapy
